ArticleNeurosurgical review2022
Paraganglioma of the cauda equina: a tertiary centre experience and scoping review of the current literature.
Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Clinicoradiological Features and Surgical Outcomes of Cauda Equina Neuroendocrine Tumors: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Cauda equina neuroendocrine tumor: a case report and diagnostic update.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Giant cauda equina neuroendocrine tumor with superficial siderosis: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Cauda equina neuroendocrine tumour complicated by intra-tumoural hemorrhage in a young male: a case report and systematic review of the literature.Journal of spine surgery (Hong Kong) · 2026Article
- Cauda equina neuroendocrine tumour of the filum terminale: a rare cause of persistent sciatica.Oxford medical case reports · 2025Article
- Intradural paragangliomas in the cauda equina region: a case report and literature review.Frontiers in oncology · 2025Article
- A rare case of cauda equina paraganglioma histologically simulating ependymoma.Surgical neurology international · 2025Article
- Concurrent multiple cerebral cavernous malformations and cauda equina paraganglioma: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Cauda equina neuroendocrine tumor: a report of three cases and review of the literature with focus on differential diagnosis and postoperative management.Neurosurgical review · 2024Review
- Cauda equina neuroendocrine tumors: A single institutional imaging review of cases over two decades.The neuroradiology journal · 2024Review
- Case report: Paraganglioma masquerading as angiosarcoma: diagnostic-dilemma in vascular tumors.Frontiers in oncology · 2024Article
- Article
- Review
- How to avoid intraoperative complications of active paragangliomas?Surgical neurology international · 2023Article
- Spinal paraganglioma at the conus medullaris mimicking schwannoma: A case report.International journal of surgery case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cauda equina paragangliomas are rare benign extra-adrenal neuroendocrine tumours arising from the neural crest cells associated with autonomic ganglia. These tumours are often mistaken preoperatively for ependymomas or schwannomas. Patients present with axial or radicular pain with or without neurological deficits. Recurrence, secretory features and length of follow-up are controversial. We conducted a retrospective cohort study of paraganglioma through searching a prospectively maintained histopathology database. Patient demographics, presentation, surgery, complications, recurrence, follow-up and outcome between 2004 and 2016 were studied. The primary aim was to collate and describe the current evidence base for recurrence and secretory features of the tumour. The secondary objective was to report outcome and follow-up strategy. A scoping review was performed in accordance with the PRISMA-ScR Checklist. Ten patients were diagnosed (M:F 7:3) with a mean age of 53.6 ± 5.1 (range 34-71 years). MRI scans revealed intradural lumbar enhancing lesions. All patients had complete microsurgical excisions without adjuvant therapy with no recurrence with a mean follow-up of 5.1 ± 1.4 years. Tumours were attached to the filum terminale. Electron microscopic images demonstrated abundant neurosecretory granules with no evidence of catecholamine production. A total of 620 articles were screened and 65 papers (including ours) combining 121 patients (mean age 48.8 and M:F 71:50) were included. The mean follow-up was 3.48 ± 0.46 (range 0.15-23 years). Back pain was the most common symptom (94%). Cure following surgery was achieved in 93% of the patients whilst 7% had recurrence. Total resection likely results in cure without the need for adjuvant therapy or prolonged follow-up. However, in certain situations, the length of follow-up should be determined by the treating surgeon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.